JMT108

DRUG3 trials

Sponsors

Shanghai JMT-Bio Inc., Conjupro Biotherapeutics, Inc.

Conditions

Advanced Malignant TumorsCancerCancer (Solid Tumors)Unresectable Locally Advanced or Metastatic MelanomaUnresectable Locally Advanced or Metastatic Urinary Tract Tumors

Phase 1

First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors

RecruitingNCT06877650

Shanghai JMT-Bio Inc.Advanced Malignant Tumors

Start: 2025-04-11End: 2029-03-30Target: 436Updated: 2026-01-29

Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors

RecruitingNCT07280832

Shanghai JMT-Bio Inc.Unresectable Locally Advanced or Metastatic Melanoma, Unresectable Locally Advanced or Metastatic Urinary Tract Tumors

Start: 2025-12-17End: 2027-05-30Target: 500Updated: 2026-08-18

A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors

RecruitingNCT07317505

Conjupro Biotherapeutics, Inc.Cancer, Cancer (Solid Tumors)

Start: 2025-12-02End: 2029-09-01Target: 270Updated: 2026-01-21

Related Papers

Abstract 4343: A novel anti-PD-1/IL-15 fusion protein JMT108 (SYS6090) with highly selective PD-1+ immune cell activation and potent anti-tumor efficacy

Cancer Research2026-04-03